Home » Teva’s Cinqair Earns FDA Approval
Teva’s Cinqair Earns FDA Approval
March 29, 2016
The FDA has approved Teva’s Cinqair for use in combination with other asthma treatments to manage severe eosinophilic asthma in adults.
In clinical trials involving 1,028 patients, those receiving Cinqair as an additional treatment experienced fewer asthma attacks and saw improved lung function compared with those getting placebo.
The drug is administered intravenously at a 3-mg dosage once every four weeks in a clinical setting to monitor for anaphylaxis.
The drug will be available in the second quarter of 2016 and is under review by the EMA and Health Canada.
Upcoming Events
-
21Oct